Showing 3371-3380 of 3539 results for "".
- Lancer Skincare Launches At-Home Producthttps://practicaldermatology.com/news/20130117-lancer_skincare_launches_at-home_product/2459635/The Lancer Skincare collection now includes the Microcurrent Powerboost, a hand-held device to help tone, tighten, and correct imbalances in the skin. According to the company, the Microcurrent Powerboost allows daily skincare products to b
- CeraVe Sun Care Partners with Olympic Swimmer Rebecca Sonihttps://practicaldermatology.com/news/20130115-cerave_sun_care_partners_with_olympic_swimmer_rebecca_soni/2459637/CeraVe Sun Care, a new line by Valeant Pharmaceuticals North America LLC, will partner with swimmer Rebecca Soni, six-time US Olympic medalist and World Record holder in the 100- and 200-meter breaststroke, as the face of the brand in 2013. The CeraVe
- Women's Dermatologic Society Event January 15https://practicaldermatology.com/news/20130111-womens_dermatologic_society_event_january_15/2459640/The Women's Dermatologic Society, sponsored by Glytone, will hold a “Look Before You Leap” Media Day 2013 on January 15, a series of desk-side appointments with the editorial community focusing on the pitfalls, complications, problems, and myths surrounding skin care and dermatology topics. Founded
- Tana Poppino to Be Celtic Complexion Sponsorhttps://practicaldermatology.com/news/20130110-tana_poppino_to_be_celtic_complexion_sponsor/2459641/Florida-based skin care company Celtic Complexion announced a sponsorship agreement with professional rodeo barrel racer Tana Poppino. Ms. Poppino, who lives in Big Cabin, OK, is a full-time contestant on the professional rodeo circuit. S
- Viscot Medical Introduces the AllSkin Plus+https://practicaldermatology.com/news/20130110-viscot_medical_introduces_the_allskin_plus/2459644/Viscot Medical released the AllSkin Plus+, a prep resistant ink marker that offers maximum visibility and prep resistance on all skin tones. According to the company, the VIXL brilliant blue ink provides enhanced visibility even after prepping with
- North American Facial Injectable Market to Hit $1.7 Billion by 2017https://practicaldermatology.com/news/20121228-north_american_facial_injectable_market_to_hit_17_billion_by_2017/2459652/According to Millennium Research Group, the North American facial injectables market, comprising botulinum toxin and dermal fillers sold in the US and Canada, will continue to show strong growth for the next five years, reaching a total value of more
- Glytone Announces Antioxidant Kit Specialhttps://practicaldermatology.com/news/20121217-glytone_announces_antioxidant_kit_special/2459657/Glytone currently offers two limited-edition antioxidant kits, featuring a selection of three products from the Glytone antioxidant range. One version includes Anti-aging Serum, Anti-aging Cream, and Anti-aging Eye Cream while the other featur
- Wells Fargo Practice Finance Helps Practices Affected by Hurricane Sandyhttps://practicaldermatology.com/news/20121204-wells_fargo_practice_finance_helps_practices_affected_by_hurricane_sandy/2459663/As the northeastern United States recovers from the effects of Hurricane Sandy, Wells Fargo Practice Finance will donate disaster relief funds to the American Dental Association Foundation and other member organizations. Existin
- Jonah Shacknai Honored at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20121203-jonah_shacknai_honored_at_cosmetic_surgery_forum/2459670/Innovators in the field of cosmetic dermatology were honored this past weekend at Cosmetic Surgery Forum, a discussion-based CME symposium held in Las Vegas and now in its fourth year. Jonah Shacknai, Founder of Medicis, was the recipient of the Lifetime Achievement in Dermatology Award. On receivin
- Xeljanz Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121118-xeljanz_approved_for_rheumatoid_arthritis/2459679/The FDA recently approved Xeljanz (tofacitinib) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to, or who are intolerant of, methotrexate. The decision comes ahead of the product's prescription drug user fee goal date of Nov